scholarly article | Q13442814 |
P50 | author | Kanneboyina Nagaraju | Q27662260 |
P2093 | author name string | Raffaella Willmann | |
TREAT-NMD Network and the Wellstone Muscular Dystrophy Cooperative Research Network | |||
P2860 | cites work | Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures | Q33975979 |
Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy | Q36841572 | ||
Mammalian animal models for Duchenne muscular dystrophy | Q37393140 | ||
P433 | issue | 7 | |
P921 | main subject | workshop | Q27556165 |
P304 | page(s) | 502-506 | |
P577 | publication date | 2009-06-26 | |
P1433 | published in | Neuromuscular Disorders | Q1981326 |
P1476 | title | Developing standard procedures for murine and canine efficacy studies of DMD therapeutics: report of two expert workshops on "Pre-clinical testing for Duchenne dystrophy": Washington DC, October 27th-28th 2007 and Zürich, June 30th-July 1st 2008. | |
P478 | volume | 19 |
Q35583176 | Enhancing translation: guidelines for standard pre-clinical experiments in mdx mice |
Q48133974 | Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy. |
Q30498131 | Gait disturbances in dystrophic hamsters |
Q89746817 | Improving translatability of preclinical studies for neuromuscular disorders: lessons from the TREAT-NMD Advisory Committee for Therapeutics (TACT) |
Q35203141 | In vivo canine muscle function assay |
Q35014916 | Interventions for muscular dystrophy: molecular medicines entering the clinic |
Q37589787 | Looking Forward to New Therapies: A Personal Perspective on the Translational Landscape for Muscular Dystrophies |
Q92464608 | Micro-dystrophin Gene Therapy Partially Enhances Exercise Capacity in Older Adult mdx Mice |
Q39663447 | Motor performance of young dystrophic mdx mice treated with long-circulating prednisolone liposomes |
Q90733720 | Mouse models for muscular dystrophies: an overview |
Q28087567 | Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus |
Q34152280 | Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials |
Q92070180 | QuantiMus: A Machine Learning-Based Approach for High Precision Analysis of Skeletal Muscle Morphology |
Q59100459 | Risks and crises for healthcare providers: the impact of cloud computing |
Q35563234 | SMASH - semi-automatic muscle analysis using segmentation of histology: a MATLAB application. |
Q34756106 | Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. |
Q28088277 | The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development |
Q34077151 | The different impact of a high fat diet on dystrophic mdx and control C57Bl/10 mice |
Q55024154 | Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands. |
Q34981147 | VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects |
Search more.